| Purpose: HMGI-C (High Mobility Group protein Isoform I-C) protein is a member of the
high-mobility group AT-hook (HMGA) family of small non-histone chromosomal protein
that can modulate transcription of an ample number of genes. Genome-wide studies
revealed up regulation of the HMGI-C gene in many human cancers. We suggested that
HMGI-C might play a critical role in the progression and migration of various tumors.
However, the exact role of HMGI-C in breast adenocarcinoma has not been cleared.
Methods: The cells were transfected with siRNAs using transfection reagent. Relative
HMGI-C mRNA and protein levels were measured by quantitative real-time PCR and
Western blotting, respectively. The cytotoxic effects of HMGI-C siRNA, Paclitaxel alone
and combination on breast adenocarcinoma cells were determined using MTT assay. The
migration after treatment by HMGI-C siRNA, Paclitaxel alone and combination were
detected by wound-healing respectively.
Results: HMGI-C siRNA significantly reduced both mRNA and protein expression levels
in a 48 hours after transfection and dose dependent manner. We observed that the
knockdown of HMGI-C led to the significant reduced cell viability and inhibited cells
migration in MDA-MB-468 cells in vitro.
Conclusion: These results propose that HMGI-C silencing and Paclitaxel treatment alone
can inhibit the proliferation and migration significantly, furthermore, synergic effect of
HMGI-C siRNA and Paclitaxel showed higher inhibition compared to mono treatment.
Taken together, HMGI-C could be used as a promising therapeutic agent in the treatment of
human breast adenocarcinoma. Therefore HMGI-C siRNA may be an effective adjuvant in
human breast adenocarcinoma. |